purine has been researched along with Recrudescence in 5 studies
1H-purine : The 1H-tautomer of purine.
3H-purine : The 3H-tautomer of purine.
9H-purine : The 9H-tautomer of purine.
7H-purine : The 7H-tautomer of purine.
Excerpt | Relevance | Reference |
---|---|---|
"Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations." | 8.12 | Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. ( Brander, D; Gonter-Aubin, K; Hanlon, A; Hill, BT; Hu, R; Kabel, C; Khajavian, S; Madanat, Y; Mato, A; Mian, A; Park, JH; Pinilla-Ibarz, J; Shadman, M; Stephens, DM; Tallman, M; Wei, W, 2022) |
"Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations." | 4.12 | Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. ( Brander, D; Gonter-Aubin, K; Hanlon, A; Hill, BT; Hu, R; Kabel, C; Khajavian, S; Madanat, Y; Mato, A; Mian, A; Park, JH; Pinilla-Ibarz, J; Shadman, M; Stephens, DM; Tallman, M; Wei, W, 2022) |
"Although hairy cell leukemia (HCL) was identified in 1958 by Bouroncle and colleagues, HCL remains in 2015 a mysterious disease." | 2.52 | New insights in the management of patients with hairy cell leukemia. ( Cornet, E; Damaj, G; Troussard, X, 2015) |
"Relapse is the leading cause of mortality in children with acute lymphoblastic leukemia (ALL)." | 1.42 | Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. ( Bai, Y; Chen, H; Chen, J; Chen, S; Chen, Y; Ding, J; Ding, L; Du, A; Ferrando, A; Gu, L; Huang, X; Jin, L; Kang, H; Kirschner-Schwabe, R; Li, B; Li, H; Li, W; Liang, H; Lu, G; Lu, H; Ma, X; Shen, S; Tang, J; Tzoneva, G; von Stackelberg, A; Wang, S; Wu, T; Yang, JJ; Yang, M; Zhang, J; Zhou, BB, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Hu, R | 1 |
Wei, W | 1 |
Mian, A | 1 |
Gonter-Aubin, K | 1 |
Kabel, C | 1 |
Mato, A | 1 |
Stephens, DM | 1 |
Hanlon, A | 1 |
Khajavian, S | 1 |
Shadman, M | 1 |
Brander, D | 1 |
Madanat, Y | 1 |
Park, JH | 1 |
Tallman, M | 1 |
Pinilla-Ibarz, J | 1 |
Hill, BT | 1 |
Tzoneva, G | 2 |
Dieck, CL | 1 |
Oshima, K | 1 |
Ambesi-Impiombato, A | 1 |
Sánchez-Martín, M | 1 |
Madubata, CJ | 1 |
Khiabanian, H | 1 |
Yu, J | 1 |
Waanders, E | 1 |
Iacobucci, I | 1 |
Sulis, ML | 1 |
Kato, M | 1 |
Koh, K | 1 |
Paganin, M | 1 |
Basso, G | 1 |
Gastier-Foster, JM | 1 |
Loh, ML | 1 |
Kirschner-Schwabe, R | 2 |
Mullighan, CG | 1 |
Rabadan, R | 1 |
Ferrando, AA | 1 |
Topp, ZZ | 1 |
Saven, A | 1 |
Li, B | 1 |
Li, H | 1 |
Bai, Y | 1 |
Yang, JJ | 1 |
Chen, Y | 1 |
Lu, G | 1 |
Ma, X | 1 |
Wu, T | 1 |
Li, W | 1 |
Lu, H | 1 |
Ding, L | 1 |
Liang, H | 1 |
Huang, X | 1 |
Yang, M | 1 |
Jin, L | 1 |
Kang, H | 1 |
Chen, S | 1 |
Du, A | 1 |
Shen, S | 1 |
Ding, J | 1 |
Chen, H | 1 |
Chen, J | 1 |
von Stackelberg, A | 1 |
Gu, L | 1 |
Zhang, J | 1 |
Ferrando, A | 1 |
Tang, J | 1 |
Wang, S | 1 |
Zhou, BB | 1 |
Cornet, E | 1 |
Damaj, G | 1 |
Troussard, X | 1 |
2 reviews available for purine and Recrudescence
Article | Year |
---|---|
Hairy cell leukemia: a 'hair-raising' update.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow; Drug Therapy, Combination; Humans; Leuke | 2014 |
New insights in the management of patients with hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B-Lymphocytes; Disease-Free Survival; Humans; Immunot | 2015 |
3 other studies available for purine and Recrudescence
Article | Year |
---|---|
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.
Topics: Humans; Leukemia, Hairy Cell; Nucleosides; Purine Nucleosides; Purines; Recurrence; Rituximab; Treat | 2022 |
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Topics: 5'-Nucleotidase; Animals; Cell Proliferation; Clonal Evolution; Disease Models, Animal; Drug Resista | 2018 |
Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.
Topics: Adolescent; Child; Child, Preschool; Exome; Feedback, Physiological; Female; High-Throughput Nucleot | 2015 |